

Dr. Kamyar Hadian (PhD)

Deputy Director and Research Group Leader
Helmholtz Munich, Research Unit Signaling and Translation
Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
[T] +49 89 3187 2664; [E] kamyar.hadian@helmholtz-munich.de

CURRENT POSITIONS

- 2025 - present **Principal Investigator**, Comprehensive Pneumology Center (CPC-M), DZL
- 2023 - present **Deputy Director**, Research Unit Signaling & Translation, Helmholtz Munich
- 2022 - present **Group Leader**, Research Group Cell Signaling & Chemical Biology, Helmholtz Munich
- 2022 - present **Director**, Compound Screening Platform, Helmholtz Munich

PREVIOUS POSITIONS

- 2015 - 2021 **Group Leader (tenured)**, Assay Development & Screening Platform
Helmholtz Zentrum München, Neuherberg, Germany
- 2016 - 2017 **Adjunct Associate Research Scientist (Collaborative Research Sabbatical)**
Columbia University, New York City, USA
- 2010 - 2015 **Junior Group Leader (tenure track)**, Assay Development & Screening Platform
Helmholtz Zentrum München, Neuherberg, Germany
- 2008 – 2010 **Postdoctoral Fellow**, Department of Cellular Signal Integration
Helmholtz Zentrum München, Neuherberg, Germany
- 2004 – 2008 **Doctoral thesis**, Institute of Virology,
Helmholtz Zentrum München

AWARDS, HONORS, and ADVISORY ACTIVITIES (selection)

- 2026 – present Elected Member, Panel “Mol and Cell Biol” at Flanders Research Foundation (FWO)
- 2025 – present Editor, Journal “Ferroptosis and Oxidative Stress” (FOS)
- 2025 – present Editor, Journal “EXO – Beyond the Cell”
- 2023 Bio^M m⁴ **Award** (TUBiRA)
- 2022 – present Elected Member, Scientific Advisory Board of ISIDORe EU Project by ERINHA
- 2016 – present Elected Member Global Council, International Chemical Biology Society (ICBS)
- 2016 Journal of Biomolecular Screening ‘Reader’s Choice **Award**’ by SLAS

PATENTS

Published and Granted

- WO/2022/078602: **Hadian K**, Schindler M, Günther M, Laufer S, Pereira Gondim MV, Ruetalo Buschinger N, Schorpp K, Wiltzer-Bach L. Flavi-Block: a pan-flavivirus inhibitor – **EP** (EP4228631B1)
- WO/2019/180207: **Hadian K**, Brenke JK, Plettenburg O, Juerjens G, Wienecke P. TRAF6 inhibitors – **USA** (US12240854B2)
- WO/2018/050286: **Hadian K**, Brenke JK, Plettenburg O, Juerjens G. TRAF6 inhibitors – **USA** (US10669278B2); **USAdiv** (US11001591B2); **EP** (EP3512852B1) **AUS** (AU2017326116B2); **CN** (CN109715631B); **JP** (JP7117293B2); **RU** (RU2770404C2)
- WO/2017/097928: **Hadian K**, Schorpp K, Sattler M, Komal S, Gopalakrishnan J. CPAP-Tubulin Module – **USA** (US10875856B2); **CN** (CN108601779B), **JP** (JP6984824B2)

Published

- WO/2024/218322: **Hadian K**, Tschuck J, Rösner M. Ferroptosis Inhibitors
- WO/2022/129210: **Hadian K**, Popowicz GM, Sattler M, Plettenburg O, Mourao A, Schorpp K, Napolitano V, Pyrc Kowczarek K, Dabrowska A, Botwina P, Milewska A, Fröhlich T. Inhibition of virus protease

FUNDING (selection) | Total: 2,001,094 €

- 2024 – 2028 Deutsche Forschungsgemeinschaft CRC/TRR 387: **462,624 Euros** (to Hadian)
Project Z02, “Drug/Probe Discovery Platform”
PIs: **Hadian**, Brunschweiler, Plettenburg and Popowicz
- 2024 – 2028 Deutsche Forschungsgemeinschaft CRC/TRR 387: **68,625 Euros** (to Hadian)
Project B05, “Targeting OTUD6B in multiple myeloma”
PIs: **Hadian** and Bassermann
- 2024 – 2026 Bio^M m⁴-Award: **532,912 Euros** (to Hadian)
Project TUBiRA, “Lead Optimization of first-in-class TRAF6-Ubc13 inhibitors for the treatment of Rheumatoid Arthritis”
PI: **Hadian**
- 2023 – 2025 Alexander von Humboldt-Stiftung: Fellowship to Alaa Bessadok: **91,200 Euros**
Project “The Drug-Death Atlas: a roadmap towards cell death prediction using graph neural network and high content screening techniques”
PIs: **Hadian** and Peng
- 2020 – 2022 BMBF Target Validation Fund: **206,783 Euros** (to Hadian)
Project ALTERNATIVE, “Targeting alternative proteasome complexes for lung cancer therapy”
PIs: **Hadian**, Meiners, Stathopoulos and Popowicz
- 2017 – 2018 Helmholtz Association Innovation Fund, PI: **Hadian**, “TRAF6-Ubc13 inhibitors: A novel strategy to target RA and other autoimmune diseases”, **282,300 Euros**

PUBLICATIONS (selection) | pubs: **83** | citations (Google Scholar): **6544** | *h*-index: **37** | # (co)-senior author

5 most important Research Articles:

- Ramani A, Pasquini G, Gerkau NJ, Jadhav V, Vinchure OS, Altinisik N, Windoffer H, Muller S, Rothenaigner I, Lin S, Mariappan A, Rathinam D, Mirsaidi A, Goureau O, Ricci-Vitiani L, D’Alessandris QG, Wollnik B, Muotri A, Freifeld L, Jurisch-Yaksi N, Pallini R, Rose CR, Busskamp V, Gabriel E, **Hadian K[#]** & Gopalakrishnan J[#] – Reliability of high-quantity human brain organoids for modeling microcephaly, glioma invasion and drug screening, *Nature Communications*, 2024
- Tschuck J, Tonnus, W, Gavali S, Kolak A, Mallais M, Maremonti F, Sato M, Rothenaigner I, Friedmann Angeli JP, Pratt DA, Linkermann A, and **Hadian K[#]** – Seratrodast inhibits ferroptosis by suppressing lipid peroxidation, *Cell Death Disease*, 2024
- Tschuck J, Padmanabhan Nair Vidya, Galhoz A, Zaratiegui C, Tai H-M, Ciceri G, Rothenaigner I, Tchieu J, Stockwell BR, Studer L, Cabianca DS, Menden MP, Vincendeau M[#], and **Hadian K[#]** – Suppression of ferroptosis by vitamin A or radical-trapping antioxidants is essential for neuronal development, *Nature Communications*, 2024
- Tschuck J, Theilacker L, Rothenaigner I, Weiß SAI, Akdogan B, Lam VT, Müller C, Graf R, Brandner S, Pütz C, Rieder T, Schmitt-Kopplin P, Vincendeau M, Zischka H, Schorpp K, and **Hadian K[#]** – Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis, *Nature Communications*, 2023
- Kraft VAN, Bezjian CT, Pfeiffer S, Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X, Anastasov N, Kössl J, Brandner S, Daniels JD, Schmitt-Kopplin P, Hauck SM, Stockwell B[#], **Hadian K[#]** and Schick JA[#] – GTP Cyclohydrolase 1/Tetrahydrobiopterin counteract ferroptosis through lipid remodeling, *ACS Central Science*, 2020 (> 1000 citations)

5 most important Review Articles:

- Tschuck J, Skafar V, Friedmann Angeli JP[#], and **Hadian K[#]** – The metabolic code of ferroptosis: nutritional regulators of cell death, *Trends in Biochemical Sciences*, 2025
- Hadian K[#]**, and Brent R Stockwell[#] – The therapeutic potential of targeting regulated non-apoptotic cell death, *Nature Reviews Drug Discovery*, 2023
- Hadian K[#]** and Stockwell BR[#] – A roadmap to creating ferroptosis-based medicines, *Nature Chemical Biology*, 2021
- Hadian K[#]** and Stockwell BR[#] – SnapShot: Ferroptosis, *Cell*, 2020
- Lin S, Schorpp K, Rothenaigner I and **Hadian K[#]** – Image-based high-content screening in drug discovery, *Drug Discovery Today*, 2020